AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 28919843
Drug: Phenylalanine (3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Phenylalanine (3 g/dose)
Trial: 12675760
Drug: 2 ml
RxNorm normalized name: ethanol 2 ML/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 ml of 1:1000 nebulized adrenaline
Trial: 12675760
Drug: 2 ml
RxNorm normalized name: ethanol 2 ML/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 ml of nebulized normal saline
Trial: 9186254
Drug: Antiepileptic polytherapy
RxNorm normalized name: ANTIEPILEPTICS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antiepileptic polytherapy
Trial: 27276401
Drug: α-lipoic acid
RxNorm normalized name: α-lipoic acid
DrugBank: Lipoic acid (DB00166)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: α-lipoic acid (ALA) at 600-1800 mg
Trial: 25876343
Drug: Comprehensive treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Comprehensive treatment (acupoint injection + neural electrical stimulation)
Trial: 30957447
Drug: Acupoint injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acupoint injection
Trial: 20458350
Drug: Alendronate (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alendronate (5 mg/day for 4 months)
Trial: 20458350
Drug: Alendronate (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alendronate (5 mg/day for 2 months after crossover)
Trial: 16077385
Drug: Dexamethasone (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dexamethasone (1 mg . kg ‐1) during induction of anesthesia
Trial: 12663440
Drug: Quinine (30
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Quinine (30 mg/kg/day continuous intravenous infusion) in combination with induction chemotherapy (idarubicine and cytarabine)
Trial: 12663440
Drug: Induction chemotherapy
RxNorm normalized name: human sputum, Bordetella pertussis infected
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Induction chemotherapy (idarubicine and cytarabine) with or without quinine
Trial: 31361094
Drug: deoxyribonucleate sodium
RxNorm normalized name: deoxyribonucleases
FDA approved: no
EMA approved: no
PMDA approved: no
Description: deoxyribonucleate sodium (75 mg via intramuscular injection every 48 hours for 1 month)
Trial: 31361094
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (standard therapy without deoxyribonucleate sodium)
Trial: 27964837
Drug: Sitagliptin plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sitagliptin plus basal insulin (glargine once daily)
Trial: 27964837
Drug: Basal-bolus regimen
RxNorm normalized name: Anacin Aspirin Regimen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Basal-bolus regimen (glargine once daily and rapid-acting insulin before meals)
Trial: 25942458
Drug: Raltegravir 400
RxNorm normalized name: raltegravir 400 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Raltegravir 400 mg two times a day for 7 days
Trial: 25942458
Drug: Atorvastatin 20
RxNorm normalized name: atorvastatin 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atorvastatin 20 mg once a day for 7 days
Trial: 25942458
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of atorvastatin 20 mg once a day + raltegravir 400 mg two times a day for 7 days
Trial: 17352026
Drug: Low-dose regimen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low-dose regimen (group A): omeprazole 20 mg b.i.d, clarithromycin 250 mg b.i.d, amoxicillin 500 mg b.i.d
Trial: 17352026
Drug: High-dose regimen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose regimen (group B): omeprazole 20 mg b.i.d, clarithromycin 500 mg b.i.d, amoxicillin 1000 mg b.i.d
Trial: 15449576
Drug: Special nutritional
RxNorm normalized name: Ocean Blue Nutritionals Omega-3 1450 Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Special nutritional formula providing 480 kcal, 31 g proteins, 120 IU vitamin E, 3.8 microg vitamin B12, 400 microg folic acid, 10(9) cfu Lactobacillus paracasei (NCC 2461), and 6 g of fructo‐oligosaccharides
Trial: 11678298
Drug: 40 mg
RxNorm normalized name: rutin 40 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 40 mg methylprednisolone acetate injection with local anesthetic (group A)
Trial: 11678298
Drug: Physical therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Physical therapy measures plus nonsteroidal anti‐inflammatory drugs (group B)
Trial: 9395778
Drug: Physostigmine salicylate,
RxNorm normalized name: Physostigmine Salicylate, 1 mg/mL injectable solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Physostigmine salicylate, 8 mg/ml, one drop instilled at 7 AM and repeated on alternate hours throughout the day
Trial: 9395778
Drug: Physostigmine salicylate,
RxNorm normalized name: Physostigmine Salicylate, 1 mg/mL injectable solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Physostigmine salicylate, 8 mg/ml
Trial: 7734028
Drug: Levosulpiride (75
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Levosulpiride (75 mg/day for 20 days)
Trial: 2438613
Drug: Induction chemotherapy
RxNorm normalized name: human sputum, Bordetella pertussis infected
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Induction chemotherapy (3 X COPP/ABVD) followed by consolidation by radiotherapy (20 Gy IF)
Trial: 2438613
Drug: Induction chemotherapy
RxNorm normalized name: human sputum, Bordetella pertussis infected
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Induction chemotherapy (3 X COPP/ABVD) followed by consolidation by chemotherapy (1 X COPP/ABVD)
Trial: 2473363
Drug: Salvage therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Salvage therapy (radiotherapy in case of persisting nodal disease; chemotherapy with 4 X CEVD in case of persisting disseminated disease)
Trial: 29856832
Drug: Insulin sensitivity
RxNorm normalized name: Fluorimax Sensitive
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Insulin sensitivity and body composition
Trial: 28452705
Drug: Normal saline
RxNorm normalized name: Normal Saline Flush
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Normal saline solution nasal-pharyngeal irrigation (NSNPI) for 30 days
Trial: 28452705
Drug: Fluticasone propionate
RxNorm normalized name: Fluticasone Propionate
DrugBank: Fluticasone propionate (DB00588)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Fluticasone propionate nasal spray (FPNS) for 30 days
Trial: 24646362
Drug: Polyphenon E
RxNorm normalized name: Polyphenon E
DrugBank: Sinecatechins (DB01266)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Polyphenon E 400 mg, 600 mg, and 800 mg (combined)
Trial: 24646362
Drug: Polyphenon E
RxNorm normalized name: Polyphenon E
DrugBank: Sinecatechins (DB01266)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Polyphenon E (all doses combined)
Trial: 19004596
Drug: Auricular acupuncture
RxNorm normalized name: fluocinolone
DrugBank: Fluocinolone (DB12553)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Auricular acupuncture as an adjunct to methadone detoxification
Trial: 19004596
Drug: Standard methadone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard methadone detoxification treatment (Control)
Trial: 17531569
Drug: Very high
RxNorm normalized name: Very high density lipoprotein
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Very high hs‐CRP levels (>7.5 mg/L)
Trial: 17531569
Drug: Very low
RxNorm normalized name: Very low fat spread
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Very low hs‐CRP levels (<=1 mg/L)
Trial: 11729476
Drug: Neoadjuvant chemotherapy
RxNorm normalized name: menthol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Neoadjuvant chemotherapy (M-VAC: methotrexate, vinblastine, adriamycin, cisplatin)
Trial: 8683846
Drug: Oral vitamin
RxNorm normalized name: vitamin A Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral vitamin A capsules given to 42 children
Trial: 7044607
Drug: Surgical treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Surgical treatment (coronary bypass surgery)
Trial: 7000170
Drug: Acyclovir 2%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acyclovir 2% ointment 5 times a day
Trial: 7000170
Drug: Idoxuridine 1%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Idoxuridine 1% ointment 5 times a day
Trial: 28814158
Drug: oxymorphone patches
FDA approved: no
EMA approved: no
PMDA approved: no
Description: oxymorphone patches + capsaicin
Trial: 28814158
Drug: oxymorphone patches
FDA approved: no
EMA approved: no
PMDA approved: no
Description: oxymorphone patches - capsaicin
Trial: 25885807
Drug: Both groups
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both groups offered nicotine replacement therapy if feasible
Trial: 16468059
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of CV with other parameters
Trial: 14649401
Drug: Warfarin treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Warfarin treatment maintained
Trial: 14649401
Drug: Warfarin stopped
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Warfarin stopped prior to surgery
Trial: 11030374
Drug: Oral food
RxNorm normalized name: Nutritional Supplement Oral Food, Solid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral food challenges with cow's milk, hen's egg, wheat, and soy
Trial: 11030374
Drug: Parenteral medication
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Parenteral medication
Trial: 11030374
Drug: Establishing intravenous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Establishing intravenous access
Trial: 7812205
Drug: Induction treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Induction treatment with human lymphoblastoid IFN alpha-n1, 3 MU/mq daily for a median of 5.7 months
Trial: 7812205
Drug: Maintenance treatment
RxNorm normalized name: Dental Resources Perio Maintenance Rinse
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Maintenance treatment with human lymphoblastoid IFN alpha-n1, 3 MU/mq weekly
Trial: 7812205
Drug: Third induction
RxNorm normalized name: human sputum, Bordetella pertussis infected
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Third induction treatment with human lymphoblastoid IFN alpha-n1
Trial: 3287839
Drug: 1-week treatment
RxNorm normalized name: Weeks and Leo Complete Lice Treatment KIT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1-week treatment with pivampicillin plus pivmecillinam
Trial: 3287839
Drug: 3-week treatment
RxNorm normalized name: Weeks and Leo Complete Lice Treatment KIT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3-week treatment with pivampicillin plus pivmecillinam
Trial: 27902522
Drug: Hydroquinone cream
RxNorm normalized name: Hydroquinone Cream
DrugBank: Hydroquinone (DB09526)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Hydroquinone cream
Trial: 26601555
Drug: Propofol (0.2-0.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Propofol (0.2-0.5 mg/kg)
Trial: 21480412
Drug: Saffron (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Saffron (100 mg daily for 6 weeks)
Trial: 16547654
Drug: Medication with
RxNorm normalized name: EUGENOL 850 mg in 1 mL DENTAL LIQUID [Walgreens Natural Eugenol/Toothache Medication with cotton pellets and tweezers]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Medication with beta blockers
Trial: 16547654
Drug: Class III
RxNorm normalized name: HLA class III antigen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Class III antiarrhythmic agents (sotalol and amiodarone)
Trial: 14535873
Drug: Esomeprazole 2
RxNorm normalized name: esomeprazole 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Esomeprazole 2 x 20 mg with clarithromycin 2 x 250 mg and metronidazole 2 x 400 mg
Trial: 14535873
Drug: Omeprazole 2
RxNorm normalized name: omeprazole 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Omeprazole 2 x 20 mg with clarithromycin 2 x 250 mg and metronidazole 2 x 400 mg
Trial: 8937280
Drug: Benznidazole (7.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Benznidazole (7.5 mg/kg daily for 60 days)
Trial: 8299527
Drug: lisinopril (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: lisinopril (5 mg/d, sometimes increased to 10 mg/d after 3 weeks)
Trial: 8299527
Drug: captopril (twice
FDA approved: no
EMA approved: no
PMDA approved: no
Description: captopril (twice daily 12.5 mg, sometimes increased to twice 25 mg after 3 weeks)
Trial: 28320259
Drug: Levosimendan (0.025
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Levosimendan (0.025 to 0.2 μg/kg/min continuous infusion)
Trial: 21964228
Drug: Multisensory stimulation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Multisensory stimulation (MSS) program, 55 minutes, twice a week for 10 weeks
Trial: 16573792
Drug: Low cholesterol
RxNorm normalized name: Cholesterol
DrugBank: Cholesterol (DB04540)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low cholesterol diet (300 mg/day)
Trial: 16573792
Drug: High cholesterol
RxNorm normalized name: Cholesterol
DrugBank: Cholesterol (DB04540)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High cholesterol diet (1300 mg/day)
Trial: 11270020
Drug: Continuous infusion
RxNorm normalized name: insulin pump cartridge,continuous infusion,BT and controller SUBCUT EACH
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous infusion of propofol
Trial: 30820338
Drug: Bolus administration
RxNorm normalized name: Peumus boldus leaf extract
DrugBank: Boldo leaf extract (DB15815)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bolus administration of propofol
Trial: 11008222
Drug: Ribavirin (600
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ribavirin (600 mg/day for 8 weeks, followed by 1,000 mg/day for 8 weeks, and then 1,200 mg/day for 8 weeks)
Trial: 1568523
Drug: 10 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mg/kg cefetamet pivoxil twice daily (n = 18)
Trial: 1568523
Drug: 20 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 mg/kg cefetamet pivoxil twice daily (n = 8)
Trial: 1568523
Drug: 30-50 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 30-50 mg/kg amoxycillin/clavulanic acid three times daily (n = 11)
Trial: 29550566
Drug: Sunitinib 50
RxNorm normalized name: sunitinib 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sunitinib 50 mg daily (4 weeks on/2 weeks off)
Trial: 27865358
Drug: 3 mg
RxNorm normalized name: boron 3 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3 mg monacolin K from RYR and 200 μg folic acid per day
Trial: 19438927
Drug: Monosodium glutamate
RxNorm normalized name: Monosodium Glutamate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Monosodium glutamate (MSG) 75 mg/kg
Trial: 27091318
Drug: Monosodium glutamate
RxNorm normalized name: Monosodium Glutamate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Monosodium glutamate (MSG) 150 mg/kg
Trial: 19438927
Drug: NaCl (24
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NaCl (24 mg/kg, placebo)
Trial: 7812004
Drug: Conventional G‐banding
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional G‐banding method
Trial: 7032828
Drug: Guanfacine (1‐‐5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Guanfacine (1‐‐5 mg daily)
Trial: 7032828
Drug: Post-treatment placebo
RxNorm normalized name: hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Post-treatment placebo period
Trial: 7032828
Drug: Abrupt discontinuation
RxNorm normalized name: guaifenesin / hydrocodone bitartrate / phenylephrine hydrochloride Oral Solution [Entex HC Discontinued]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Abrupt discontinuation of guanfacine
Trial: 24005134
Drug: Levobupivacaine hydrochloride
RxNorm normalized name: Levobupivacaine Hydrochloride
DrugBank: Levobupivacaine (DB01002)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Levobupivacaine hydrochloride (5 mL, chirocaine 25 mg/10 mL) soaked PVA sponge
Trial: 24005134
Drug: Saline (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Saline (5 mL) soaked PVA sponge
Trial: 19435690
Drug: S-GemOx (gemcitabine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: S-GemOx (gemcitabine 1,000 mg/m2, 100-minute infusion D1 followed by oxaliplatin 100 mg/m2, 120-minute infusion)
Trial: 16963671
Drug: Montelukast, 10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Montelukast, 10 mg/d for 8 weeks
Trial: 11407865
Drug: Recombinant human
RxNorm normalized name: Recombinant human TNF
DrugBank: Etanercept (DB00005)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Recombinant human growth hormone alone or together with glutamine with or without a low-fat diet containing high-carbohydrate (fibre)
Trial: 7960545
Drug: Lymphoscintigraphy using
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lymphoscintigraphy using colloid agents labelled with gold and technetium (99mTc‐pertechnetate)
Trial: 18636354
Drug: Somatostatin combined
RxNorm normalized name: somatostatin
DrugBank: Somatostatin (DB09099)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Somatostatin combined with oral vancomycin
Trial: 16549021
Drug: Seal oil
RxNorm normalized name: seal oil
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Seal oil administration (n-3 polyunsaturated fatty acid rich seal oil)
Trial: 16549021
Drug: Soy oil
RxNorm normalized name: Hydrogenated soy oil
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Soy oil administration (n-6 fatty acid rich)
Trial: 11151866
Drug: 200 mg
RxNorm normalized name: RNA 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200 mg of erythromycin i.v.
Trial: 11151866
Drug: 4 mg
RxNorm normalized name: lutein 4 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4 mg of i.v. ondansetron (serotonin receptor antagonist) pretreatment
Trial: 8466682
Drug: Zidovudine 500
RxNorm normalized name: Zidovudine
DrugBank: Zidovudine (DB00495)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Zidovudine 500 mg per day (group A)
Trial: 8466682
Drug: Zidovudine 1000
RxNorm normalized name: Zidovudine
DrugBank: Zidovudine (DB00495)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Zidovudine 1000 mg per day (group B)
Trial: 3541414
Drug: 80 mg
RxNorm normalized name: RNA 180 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 80 mg isosorbide dinitrate (ISDN, once-daily) plus 120 mg verapamil (t.i.d.)
Trial: 3541414
Drug: 80 mg
RxNorm normalized name: RNA 180 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 80 mg isosorbide dinitrate (ISDN, once-daily) plus 80 mg propranolol (b.i.d.)
Trial: 3541414
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of all three drugs (ISDN, verapamil, propranolol)
Trial: 22992762
Drug: Initiation of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Initiation of bisphosphonate treatment at two weeks after the operation (Group I, n = 24)
Trial: 22992762
Drug: Initiation of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Initiation of bisphosphonate treatment at three months (Group II, n = 26)
Trial: 11873025
Drug: Ropivacaine 0.17%,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ropivacaine 0.17%, 14 ml, administered epidurally during the diurnal period (morning and afternoon)
Trial: 11873025
Drug: Ropivacaine 0.17%,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ropivacaine 0.17%, 14 ml, administered epidurally during the nocturnal period (night and evening)
Trial: 10350384
Drug: Dirithromycin (500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dirithromycin (500 mg od for 5 days)
Trial: 10350384
Drug: Erythromycin (250
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Erythromycin (250 mg qid for 7 days)
Trial: 7858733
Drug: Daily subcutaneous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily subcutaneous growth hormone (GH) for 5 months
Trial: 6132524
Drug: Acebutol (400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acebutol (400 to 800 mg daily)
Trial: 6132524
Drug: Metoprolol (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metoprolol (200 to 400 mg daily)
Trial: 30998402
Drug: Suture-Spanning Augmentation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Suture-Spanning Augmentation of Single-Row Repair (SSA-SR)
Trial: 22800876
Drug: Financial reinforcement
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Financial reinforcement interventions (longer duration, $50 or more per week, at least weekly reinforcement)
Trial: 17578312
Drug: Liqi Kuanxiong
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Liqi Kuanxiong Huoxue method (LKH) in addition to conventional treatment
Trial: 17578312
Drug: Conventional treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional treatment (nitrate, diltiazem hydrochloride, etc.)
Trial: 15224278
Drug: 5 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 mg/kg infliximab (group II)
Trial: 15224278
Drug: 5 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 mg/kg infliximab at weeks 2 and 6, followed by 10 mg/kg thereafter (group III)
Trial: 12044534
Drug: Interferon alpha‐2b
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Interferon alpha‐2b (6 MU three times per week for 24 weeks followed by 3 MU three times per week for 24 weeks) in combination with ribavirin for 48 weeks (group B)
Trial: 12044534
Drug: Daily interferon
RxNorm normalized name: Interferon Gamma
DrugBank: Interferon Gamma (DB15753)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily interferon alpha‐2b (3 MU per day for 24 weeks followed by 3 MU three times per week for 24 weeks) and ribavirin (group C)
Trial: 12044534
Drug: Combination therapy
RxNorm normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination therapy with three times weekly interferon and ribavirin
Trial: 12044534
Drug: Daily interferon
RxNorm normalized name: Interferon Gamma
DrugBank: Interferon Gamma (DB15753)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily interferon and ribavirin